CRO Beardsworth poised to move ahead with founder's vision

Tuesday, April 5, 2011 09:00 AM

Senior management of Beardsworth Consulting say they will continue to carry out the vision of company founder, president and CEO Donna E. Beardsworth, who died suddenly March 22 at age 54.

New company president and CEO Michael O’Brien had recently returned the CEO post to Donna Beardsworth after 4½ years. The two were readying an announcement to be made at the Partnerships in Clinical Trials conference last week in Phoenix that O’Brien would be stepping into a business development role. Now, he has stepped back into the CEO post.

“Now, in this role, it takes on a whole new meaning,” O’Brien said, “continuing to shine the spirit of Donna. Her mission was to help sick patients—it’s a compelling motivation.”

Beardworth Consulting is a specialty CRO focusing on complex clinical trials for difficult therapeutic areas, particularly oncology and vaccines. Donna Beardsworth founded the company, based in Flemington, N.J., 25 years ago, making it one of the oldest woman-owned CROs.

Donna Beardworth grew up in Woodbury, Conn., and earned a B.A. in Biological Sciences and an M.A. in Biochemistry from Mount Holyoke College.  She worked in clinical research at Massachusetts General Hospital for six years following graduation. O’Brien said through her work at MGH and Johnson & Johnson, she had both treated patients and ushered drugs through to FDA approval, experiencing the full drug-development process. She saw the potential to combine the various parts into one company.

Beardsworth Consulting is certified by the Women’s Business Enterprise (WBENC). With 45 full-time employees, the company saw 30% growth in the first quarter of 2011. Of its business, 75% comes from repeat clients.

O’Brien said the company is well-poised for growth. Coming into 2011 with its healthiest backlog ever, first-quarter revenues exceeded targets. Moving forward, he said, the company is looking to combine its oncology and vaccine specialties to pursue oncology vaccine opportunities.

“Of our eight senior managers, we average eight to 10 years working together,” O’Brien said. “We’re in a very good position to carry her vision forward.”

 --Cheryl Rosenfeld

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs